Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1016/j.ejca.2015.08.012

http://scihub22266oqcxt.onion/10.1016/j.ejca.2015.08.012
suck pdf from google scholar
C4821004!4821004!26364516
unlimited free pdf from europmc26364516    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid26364516      Eur+J+Cancer 2015 ; 51 (17): 2689-97
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Long term Survival with CTLA-4 blockade Using Tremelimumab #MMPMID26364516
  • Eroglu Z; Kim DW; Wang X; Camacho LH; Chmielowski B; Seja E; Villanueva A; Ruchalski K; Glaspy JA; Kim KB; Hwu WJ; Ribas A
  • Eur J Cancer 2015[Nov]; 51 (17): 2689-97 PMID26364516show ga
  • Purpose: One of the hallmarks of cancer immunotherapy is the long duration of responses, evident with cytokines like interleukin-2 or a variety of cancer vaccines. However, there is limited information available on very long term outcomes of patients treated with anti-CTLA-4 antibodies. Tremelimumab is an anti-CTLA-4 antibody of Ig G2 istoype initially tested in patients with advanced melanoma over 12 years ago. Methods: We reviewed the outcomes of patients with advanced melanoma enrolled in four phase 1 and 2 tremelimumab trials at two sites to determine response rates and long-term survival. Results: A total of 143 patients were enrolled at two institutions from 2002 to 2008. Tremelimumab administration varied between a single dose of 0.01 mg/kg and 15 mg/kg every 3 months. Median overall survival was 13 months (95% CI, 10?16.6), ranging from less than a month to 12+ years. An objective response rate of 15.6% was observed, with median duration of response of 6.5 years, range of 3 to 136+ months. The Kaplan-Meier estimated 5 year survival rate was 20% (95% CI, 13?26%), with 10 and 12.5 year survival rates of 16% (95% CI, 9?23%). Conclusions: CTLA-4 blockade with tremelimumab can lead to very long duration of objective anti-tumor responses beyond 12 years.
  • ä


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box